The Rolandic epilepsy/ESES/Landau-Kleffner Syndrome and correlation with Language impairment study

Completed

Conditions: Epilepsy
10039911

Registration Number: NL-OMON36427

Lead Sponsor: Epilepsiecentrum Kempenhaeghe

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 45

Inclusion Criteria

• Diagnosis of Rolandisch epilepsy, ESES, ESES-like or Landau-Kleffner syndrome
• Age of 8 to 18 years
• Clinical and electroencephalographic evidence of seizures.
• Non-symptomatic epilepsy;Healthy control group
Inclusion criteria for healthy control children:
• Children aged 8 to 16 years
• Normal intelligence/following regular schools

Exclusion Criteria

• MRI lesions on previous structural brain MRI- or CT-scans or symptomatic epilepsy (e.g. tumours, vascular abnormalities, congenital dysgenesia)
• Progressive neurological disorders
• Other diseases/ causes that may underlie cognitive impairment (i.e. psychiatric diseases)
• Vision less than +4.5D or - 4.5D
• Claustrophobia
• Metal implants or other contraindication for MRI
• Parents not willing to provide informed consent;Healthy control children
Exclusion criteria for the healthy control children:
• Medical history of head trauma or other diseases/ causes that may underlie cognitive impairment (i.e. psychiatric diseases)
• Inability to speak/understand the Dutch language
• Vision less than +4.5D or - 4.5D
• Claustrophobia
• Metal implants or other contraindication for MRI
• Parents not willing to provide informed consent
• Parents who do not want to get informed whenever structural abnormalities are found during imaging

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Abnormalities that are related to Rolandic epilepsy, ESES-like, ESES, LKS,<br /><br>language impairment, cognitive impairment and/or refractoriness. Endpoints are<br /><br>the microstructural and functional integrity, seizure history, IQ-scores, and<br /><br>response to anti-epileptic drug treatment or other treatment (corticosteroids),<br /><br>EEG-parameters (localisation and frequency of epileptic activity). (For<br /><br>further information see: Methods, primary study parameters/endpoints)</p><br>

Secondary Outcome Measures